Skip to main content
Arthur Xintian You on Muck Rack

Arthur Xintian You

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Arthur Xintian

Contact Arthur Xintian, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study

|
By Yonina R. Murciano-Goroff, Antoine Hollebecque, Rebecca S. Heist, Philippe A. Cassier, Ji-Youn Han, So Yeon Kim, Joshua K. Sabari, Diego Tosi, Adrian G. Sacher, Timothy Burns, Toshio Shimizu, Alexander Spira, Carlos Gomez-Roca, Amita Patnaik, Rasha Cosman, J. Nicholas Bodor, Misako Nagasaka, Raimund M. Peter, Aaron Fink, Aaron Chen, Geoffrey R. Oxnard, Yasutoshi Kuboki, Takafumi Koyama, Natraj Reddy Ammakkanavar, Arthur Xintian You, Samuel C. McNeely, Melinda D. Willard
| Nature Verified
Abstract This multicenter, first-in-human Phase 1 study (NCT04956640) evaluated olomorasib (LY3537982), a next-generation KRAS G12C inhibitor designed to enhance target occupancy at low absolute exposures.
Open in Who Shared Issue with article?
See all 1 articles